Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




基态人类干细胞促进再生医学和人类发展的研究

By LabMedica International staff writers
Posted on 03 Dec 2013
发现了一种维持人类诱导多能干细胞(iPS 细胞)最早期、最原始、最基态的方法,预期该方法能促进这些干细胞在再生医学、患者特定 iPS 细胞疾病模型,以及在早期人类发展的体外和体内研究中的应用。

诱导多能干细胞形成的方法通常为:向诸如皮肤细胞的此类成人细胞基因组中插入 4 个基因,然后使用鸡尾酒式组合的生长因子培养改良的细胞。然后分化的细胞还原为胚胎干细胞类似状态,而不是成为多种不同细胞类型的成熟细胞。此问题的症结在于,缺乏将干细胞长期保持在未分化状态的方法。

Weizmann Institute of Science (Rehovot, Israel) 的研究人员使用小鼠和人类细胞进行研究,努力解决此问题。他们尤其感兴趣建立一种技术,将人类的 iPS 细胞保持在最早期基态,以模拟小鼠的干细胞行为,后者能更长时间自然的保持未分化状态。

研究人员在 2013 年 10 月 30 日的《自然杂志》(Nature) 网络版中报道,已成功确立了指定条件,以便于将已经成为始发态人类胚胎干细胞的细胞衍生为未经基因改良的人类基态多能干细胞、经由 iPS 细胞重新编程从体细胞衍生为未经基因改良的人类基态多能干细胞,或直接从囊胚泡衍生为未经基因改良的人类基态多能干细胞。新的基态多能细胞保留了与小鼠基态胚胎干细胞高度相似的分子特性和功能特性,并有别于普通的始发人类多能干细胞。

Related Links:
Weizmann Institute of Science

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.